Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Cameron

Showing results (101-110 of 134) with videos related to

Pageof 14
Sort By:
The Oncologist|January 31, 2023
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer TreatmentKarin Purshouse, John P Thomson, Mahéva Vallet, et al.
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2012
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012Matthias Preusser, Frank Winkler, Laurence Collette, et al.
The Oncologist|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBCNaoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Lancet (London, England)|February 1, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trialJanet A Dunn, Peter Donnelly, Nada Elbeltagi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
The New England Journal of Medicine|March 9, 2022
Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 14

Showing results (101-110 of 134) with videos related to

Sort By:
Pageof 14
The Oncologist|January 31, 2023
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer TreatmentKarin Purshouse, John P Thomson, Mahéva Vallet, et al.
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
European Journal of Cancer (Oxford, England : 1990)|August 14, 2012
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012Matthias Preusser, Frank Winkler, Laurence Collette, et al.
The Oncologist|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBCNaoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
Breast Cancer Research and Treatment|March 1, 2023
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II studyAilsa J Oswald, Stefan N Symeonides, Duncan Wheatley, et al.
The Lancet. Oncology|May 16, 2015
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trialHelena M Earl, Louise Hiller, Janet A Dunn, et al.
Lancet (London, England)|February 1, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trialJanet A Dunn, Peter Donnelly, Nada Elbeltagi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.
The New England Journal of Medicine|March 9, 2022
Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
Pageof 14